Supplementary Figure 3.
Overview of all conducted experiments where mineralocorticoid receptor agonists and mineralocorticoid receptor antagonists were administered.
All treatments were performed according to the intermittent treatment paradigm as described in the manuscript, except for Subfigure C (continuous treatment with spironolactone) and Subfigure E (45 minutes for all treatment groups to assess transient SGK1 upregulation).
Effects on corticosteroid target genes after administration of either mineralocorticoid receptor agonists or antagonists were not observed in any of the 5 different donors. Every subfigure represents an experiment with choroidal endothelial cells derived from 1 donor (ages: S4A: 78, S4B: 94, S4C: 69, S4D: 57, S4E: 86). Error bars represent standard deviation. * p-value < 0.05; ** p-value < 0.01; *** p-value = 0.0002; **** p-value < 0.0001. 
